Status:
COMPLETED
Study to Evaluate the Clinical Outcome in High Risk Patients Who Received Empirical Antifungal Therapy
Lead Sponsor:
Fortis Hospital, India
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Antifungal Therapy
Eligibility:
All Genders
18-75 years
Brief Summary
Retrospective, observational study To study the effect of Empirical Antifungal therapy on clinical outcome in high risk patients with suspected Invasive Fungal Infection admitted in ICU/Critical care ...
Detailed Description
Study Objectives Primary Objective: \- To study the effect of Empirical Antifungal therapy on clinical outcome in high risk patients with suspected Invasive Fungal Infection admitted in ICU/Critical...
Eligibility Criteria
Inclusion
- All Non-neutropenic patients (18-75yrs) admitted in the intensive care/critical care unit who are prescribed any form of pre-emptive / empirical Antifungal therapy during the specified study duration period
Exclusion
- Neutropenic patients
- Patients with proven invasive fungal infections where antifungal therapy was initiated after the confirmation of Invasive fungal infection/Candidemia
- Patients who received prophylactic antifungal agents
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01439646
Start Date
August 1 2011
End Date
March 1 2012
Last Update
August 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Raja dhar
Kolkata, West Bengal, India, 700107